These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 8968344)
1. Inotropic and coronary vasodilatory actions of the K-adenosine triphosphate channel modulator nicorandil in human tissue. Müller-Ehmsen J; Brixius K; Hoischen S; Schwinger RH J Pharmacol Exp Ther; 1996 Dec; 279(3):1220-8. PubMed ID: 8968344 [TBL] [Abstract][Full Text] [Related]
2. Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue. Brixius K; Mohr V; Müller-Ehmsen J; Hoischen S; Münch G; Schwinger RH Br J Pharmacol; 1998 Sep; 125(1):41-8. PubMed ID: 9776342 [TBL] [Abstract][Full Text] [Related]
3. Cardiac inotropic as well as coronary and pulmonary artery actions of epinine in human isolated tissues. Schwinger RH; Böhm M; Schulz C; Schmidt U; Schmidt U; Schmid B; Dienemann H; Reichart B; Erdmann E J Pharmacol Exp Ther; 1993 Apr; 265(1):346-57. PubMed ID: 8386240 [TBL] [Abstract][Full Text] [Related]
4. Nicorandil-induced vasorelaxation: functional evidence for K+ channel-dependent and cyclic GMP-dependent components in a single vascular preparation. Meisheri KD; Cipkus-Dubray LA; Hosner JM; Khan SA J Cardiovasc Pharmacol; 1991 Jun; 17(6):903-12. PubMed ID: 1714013 [TBL] [Abstract][Full Text] [Related]
5. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. Borg C; Mondot S; Mestre M; Cavero I J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478 [TBL] [Abstract][Full Text] [Related]
6. The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. Magnon M; Durand I; Cavero I J Pharmacol Exp Ther; 1994 Mar; 268(3):1411-8. PubMed ID: 7908056 [TBL] [Abstract][Full Text] [Related]
7. Inotropic effect of the cardioprotective agent 2,3-butanedione monoxime in failing and nonfailing human myocardium. Schwinger RH; Böhm M; Koch A; Morano I; Rüegg JC; Erdmann E J Pharmacol Exp Ther; 1994 May; 269(2):778-86. PubMed ID: 8182546 [TBL] [Abstract][Full Text] [Related]
8. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue. Brixius K; Gross T; Tossios P; Geissler HJ; Mehlhorn U; Schwinger RH; Hekmat K Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):708-13. PubMed ID: 16173926 [TBL] [Abstract][Full Text] [Related]
9. Regional expression and functional characterization of the L-type Ca2+-channel in myocardium from patients with end-stage heart failure and in non-failing human hearts. Schwinger RH; Hoischen S; Reuter H; Hullin R J Mol Cell Cardiol; 1999 Jan; 31(1):283-96. PubMed ID: 10072735 [TBL] [Abstract][Full Text] [Related]
10. The risk of myocardial stunning is decreased concentration-dependently by KATP channel activation with nicorandil before high K+ cardioplegia. Sugimoto S; Iwashiro K; Monti F; Dawodu AA; Schiariti M; Puddu PE Int J Cardiol; 1995 Jan; 48(1):11-25. PubMed ID: 7744533 [TBL] [Abstract][Full Text] [Related]
11. Enantioselective inotropic actions of the Na+-channel activators BDF 9148, BDF 9196 and BDF 9167 in human failing and nonfailing myocardium. Schwinger RH; Müller-Ehmsen J; Böhm M; Erdmann E J Pharmacol Exp Ther; 1996 Mar; 276(3):1180-8. PubMed ID: 8786551 [TBL] [Abstract][Full Text] [Related]
12. [Effects of nicorandil, a potassium agonist, on the human umbilical artery. Role of the vascular endothelium]. Tiritilli A; Levy P; Haïat R Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1095-9. PubMed ID: 8572852 [TBL] [Abstract][Full Text] [Related]
13. Vasodilative effect of nicorandil on coronary artery. Miyazaki Y; Ogawa K; Satake T; Sugiyama S; Ozawa T Arzneimittelforschung; 1985; 35(2):504-7. PubMed ID: 3158319 [TBL] [Abstract][Full Text] [Related]
14. Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo. Hirata Y; Kanada A; Miyai H; Mabuchi Y; Aisaka K Arzneimittelforschung; 1999 Mar; 49(3):199-206. PubMed ID: 10219462 [TBL] [Abstract][Full Text] [Related]
16. Acute dilatory and negative inotropic effects of homocysteine are inhibited by an adenosine blocker. Kennedy RH; Owings R; Joseph J; Melchert RB; Hauer-Jensen M; Boerma M Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):340-4. PubMed ID: 16620298 [TBL] [Abstract][Full Text] [Related]
17. Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways. Pérez-Vizcaíno F; Cogolludo AL; Villamor E; Tamargo J Br J Pharmacol; 1998 Mar; 123(5):847-54. PubMed ID: 9535012 [TBL] [Abstract][Full Text] [Related]
18. Pretreatment with the adenosine triphosphate-sensitive potassium channel opener nicorandil and improved myocardial protection during high-potassium cardioplegic hypoxia. Sugimoto S; Puddu PE; Monti F; Schiariti M; Campa PP; Marino B J Thorac Cardiovasc Surg; 1994 Sep; 108(3):455-66. PubMed ID: 8078338 [TBL] [Abstract][Full Text] [Related]
19. Effects of nicotinamide on cardiac contraction force and slow inward current. Mao XM; Li DM; Zhou CM; Wang XW; Zhang KJ Zhongguo Yao Li Xue Bao; 1993 Nov; 14(6):514-6. PubMed ID: 7516609 [TBL] [Abstract][Full Text] [Related]
20. Relaxant effect of nicorandil on the tonic contraction of the canine large coronary artery induced by phorbol 12,13-dibutylate. Kuromaru O; Sakai K Arch Int Pharmacodyn Ther; 1995; 330(1):25-38. PubMed ID: 8849308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]